TRAM-34 | CAS# 289905-88-0 | Inhibitor

TRAM-34
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 522416

CAS#: 289905-88-0

Description: TRAM-34 is a highly selective blocker of intermediate conductance Ca2+-activated K+ channels (KCa3.1) that has been shown to suppress the reactivation of lymphocytes by mitogenic stimuli without blocking cytochrome P450.

Chemical Structure

TRAM-34

CAS# 289905-88-0

Instruction

Theoretical Analysis

MedKoo Cat#: 522416
Name: TRAM-34
CAS#: 289905-88-0
Chemical Formula: C22H17ClN2
Exact Mass: 344.11
Molecular Weight: 344.840
Elemental Analysis: C, 76.63; H, 4.97; Cl, 10.28; N, 8.12

Price and Availability

Size	Price	Availability
10mg	USD 230	2 Weeks
25mg	USD 385	2 Weeks
50mg	USD 630	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: TRAM-34; TRAM34; TRAM 34

IUPAC/Chemical Name: 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole

InChi Key: KBFUQFVFYYBHBT-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H17ClN2/c23-21-15-8-7-14-20(21)22(25-17-9-16-24-25,18-10-3-1-4-11-18)19-12-5-2-6-13-19/h1-17H

SMILES Code: C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CC=N4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 344.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Ye JH, Pao LH. Using Visualized Matrix Effects to Develop and Improve LC-MS/MS Bioanalytical Methods, Taking TRAM-34 as an Example. PLoS One. 2015 Apr 24;10(4):e0118818. doi: 10.1371/journal.pone.0118818. eCollection 2015. PubMed PMID: 25909956; PubMed Central PMCID: PMC4409340.

2: Lin H, Zheng C, Li J, Yang C, Hu L. Ca2+ -activated K+ channel-3.1 blocker TRAM-34 alleviates murine allergic rhinitis. Int Immunopharmacol. 2014 Dec;23(2):642-8. PubMed PMID: 25466273.

3: Ongerth T, Russmann V, Fischborn S, Boes K, Siegl C, Potschka H. Targeting of microglial KCa3.1 channels by TRAM-34 exacerbates hippocampal neurodegeneration and does not affect ictogenesis and epileptogenesis in chronic temporal lobe epilepsy models. Eur J Pharmacol. 2014 Oct 5;740:72-80. doi: 10.1016/j.ejphar.2014.06.061. Epub 2014 Jul 10. PubMed PMID: 25016931.

4: Freise C, Querfeld U. Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34. Pharmacol Res. 2014 Jul;85:6-14. doi: 10.1016/j.phrs.2014.04.013. Epub 2014 May 6. PubMed PMID: 24813858.

5: Agarwal JJ, Zhu Y, Zhang QY, Mongin AA, Hough LB. TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS One. 2013 May 7;8(5):e63028. doi: 10.1371/journal.pone.0063028. Print 2013. PubMed PMID: 23667566; PubMed Central PMCID: PMC3646888.

6: Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau AP, Begueret H, Wulff H, Marthan R, Bradding P, Berger P. Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. Am J Respir Cell Mol Biol. 2013 Feb;48(2):212-9. doi: 10.1165/rcmb.2012-0103OC. Epub 2012 Nov 29. PubMed PMID: 23204391; PubMed Central PMCID: PMC4035224.

7: Freise C, Ruehl M, Seehofer D, Hoyer J, Somasundaram R. The inhibitor of Ca(2+)-dependent K+ channels TRAM-34 blocks growth of hepatocellular carcinoma cells via downregulation of estrogen receptor alpha mRNA and nuclear factor-kappaB. Invest New Drugs. 2013 Apr;31(2):452-7. doi: 10.1007/s10637-012-9879-6. Epub 2012 Oct 2. PubMed PMID: 23054207.

8: Quast SA, Berger A, Buttstädt N, Friebel K, Schönherr R, Eberle J. General Sensitization of melanoma cells for TRAIL-induced apoptosis by the potassium channel inhibitor TRAM-34 depends on release of SMAC. PLoS One. 2012;7(6):e39290. doi: 10.1371/journal.pone.0039290. Epub 2012 Jun 18. PubMed PMID: 22723988; PubMed Central PMCID: PMC3377761.

9: Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. J Cereb Blood Flow Metab. 2011 Dec;31(12):2363-74. doi: 10.1038/jcbfm.2011.101. Epub 2011 Jul 13. PubMed PMID: 21750563; PubMed Central PMCID: PMC3323185.

10: Roy JW, Cowley EA, Blay J, Linsdell P. The intermediate conductance Ca2+-activated K+ channel inhibitor TRAM-34 stimulates proliferation of breast cancer cells via activation of oestrogen receptors. Br J Pharmacol. 2010 Feb 1;159(3):650-8. doi: 10.1111/j.1476-5381.2009.00557.x. Epub 2009 Dec 24. PubMed PMID: 20050851; PubMed Central PMCID: PMC2828028.

Your view history

TRAM-34 featured